Delta-9-tetrahydrocannabinol delays the gastric emptying of solid food in humans: A double-blind, randomized study

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 1, 1999, Pages 77-80

  McCallum, R W ^a   Soykan, I ^a   Sridhar, K R ^b   Ricci, D A ^b   Lange, R C ^b   Plankey, M W ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRONABINOL; RADIOISOTOPE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH EMPTYING; TEST MEAL;

ADULT; ANTIEMETICS; DOUBLE-BLIND METHOD; FEMALE; FOOD; GASTRIC EMPTYING; HUMANS; MALE; NAUSEA; RADIOPHARMACEUTICALS; REFERENCE VALUES; TECHNETIUM; TETRAHYDROCANNABINOL; TIME FACTORS; VOMITING;

EID: 0032940913     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00441.x     Document Type: Article

References (18)

1. 1 Voth EA, Schwartz RH. Medicinal applications of delta-9-tetrahydrocannabinol. Ann Intern Med 1997; 126: 791-8.
2. 2 Ekert H, Waters KD. Jurk IH, et al. Amelioration of cancer chemotherapy induced nausea and vomiting by Delta-9-THC. Med J Aust 1979; 2: 657-9.
3. 3 Sallan SE, Cronin C, Zelen M, Zanberg NE. Antiemetics in patients receiving chemotherapy for cancer. New Engl J Med 1980; 302: 135-8.
4. 4 Sallan SE, Zinberg NF, Frei E. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. New Engl J Med 1975; 293: 795-7.
5. 5 Gralla RJ. Itri LM, Pisko SE, et al. Antiemetic efficacy of high dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy induced nausea and vomiting. New Engl J Med 1981; 305: 905-9.
6. 6 Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med 1983; 98: 86-95.
7. 7 Chang AE, Shilling DJ, Stillman RC, et al. Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. Ann Intern Med 1979; 91: 819-24.
8. 8 McCallum RW, Grill BB, Lange R, Planky M, Glass EE, Greenfield DG. Definition of a gastric emptying abnormality in patients with anorexia nervosa. Dig Dis Sci 1985; 30: 713-22.
9. 9 Wall ME, Harvey TM, Bursey JT, et al. Analytical methods in the determination of cannabinol in biological materials. In: Willette RE, ed. NIDA Research Monograph: Cannabinoid Assay in Humans. Rockville, MD: NIDA, 1976.
10. 10 Glantz SA. Primer of Bio-Statistics. New York: McGraw-Hill. Inc., Health Professions Division. 1992.
11. 11 Chester GB, Dall CJ, Everingham M, et al. The effect of cannabinoids on intestinal mobility and their antinociceptive effect in mice. Br J Pharmacol 1973; 45: 588-94.
12. 12 Shook JE, Dewey WL, Burks TF. The central and peripheral effects of delta-9-tetrahydrocannabinol on gastrointestinal transit in mice. NIDA Res Monogr 1986; 67: 222-7.
13. 13 Jones RT. Cannabis and health. Annu Rev Med 1983; 34: 247-58.
14. 14 Bateman DN. Delta-9-tetrahydrocannabinol and gastric emptying. Br J Pharmacol 1983; 15: 749-51.
15. 15 Minami H, McCallum RW. The physiology and pathophysiology of gastric emptying in humans. Gastroenterology 1984; 86: 1592-610.
16. 16 Benowitz MD, Jones RT. Effects of delta-9-tetrahydrocannabinol on drug distribution and metabolism. Clin Pharmacol Ther 1975; 22: 259-68.
17. 17 Ritchie JM. The aliphatic alcohols. In: Gilman AG, Goodman LS & Gilman A, eds. The Pharmacologic Basis of Therapeutics. New York: MacMillan Publishing Co, 1980: 376-90.
18. 18 Soykan I, McCallum RW. Nausea, vomiting and anorexia. In: Stein JH, ed. Internal Medicine. St Louis, Missouri: Mosby Inc., 1998: 2025-30.